Drug Search Results
More Filters [+]

NN-9925

Alternative Names: nn-9925, nn9925, nn 9925
Latest Update: 2017-02-28
Latest Update Note: Clinical Trial Update

Product Description

Novo Nordisk was developing nn-9925, an oral GLP-1 Agonist for Diabetes Mellitus, Type 2

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NN-9925

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NN9925-3779

P1

Completed

Type 2 Diabetes

2010-09-16

Recent News Events

Date

Type

Title